Clinical classification of BC based on the expression of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) has resulted in three broad subtypes, which are luminal BC, HER2-positive (HER2+) BC and triple-negative breast cancer (TNBC). Here, PGR is linked to triple-negative breast carcinoma.